Research Study for Patients With Neurological Diseases Which Evaluates the Patient Experience of the MemorEM Device

eQ8Health Corporation d/b/a CareONE Concierge

Status

Invitation-only

Conditions

Alzheimer Disease

Frontotemporal Dementia

Posterior Cortical Atrophy (PCA)

Cortico Basal Degeneration

Parkinson Disease

Dementia

Neurological Diseases or Conditions

Treatments

Device: MemorEM

Study type

Interventional

Funder types

Industry

Identifiers

NCT07222605

CareONE-002

Details and patient eligibility

About

Primary Objective:

The primary objective of this pilot study is to gain voluntary feedback from patients with neurological diseases and their caregivers regarding their experiences using the MemorEM head device. This information may help in new designs of the MemorEM and suggest ways to increase compliance for future clinical trials and eventual commercialization.

Secondary Objective:

The secondary objective is to note areas of potential improvement in the progression of the subject's neurological disease and identify the potential for the MemorEM to treat neurological diseases other than Alzheimer's disease. The investigators are also interested in Alzheimer's variants like those with ApoE4 alleles (none of the participants in the 8-person pilot were Apo-E4 positive), known mutations causing early onset Alzheimer's, and Posterior Cortical Atrophy.

Full description

Study Duration:

The study will be open-ended with patients continuing use of the MemorEM as they wish or when NeuroEM Therapeutics recalls the device. It is expected but optional that patients will use the devices for approximately two years.

Study Design:

This study will focus on the "patient experience" of using the MemorEM device over an extended time period. Patients will remain under the care of their physicians and will provide brief descriptions of their device experiences and any suggestions for improvements. This study will not require any interventions other than using the MemorEM device, which was rated as Non-Significant Risk by the Western IRB for the previous pilot trial including two extensions that raised no safety concerns over the two and a half years of treatment.

Study Population:

The study population will consist of various patients suffering from diagnosed neurological diseases. Patients may be selected from those diagnosed with Alzheimer's disease, Frontotemporal dementia, Posterior cortical atrophy, Corticobasal dementia, Parkinson's disease, and other neurological diseases.

Enrollment

1,000 estimated patients

Sex

All

Ages

45 to 100 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patient diagnosed with a neurological disease involving aggregated proteins such as Alzheimer's and its variants, Parkinson's, Frontotemporal dementia, Amyotrophic lateral sclerosis, Tauopathies, and other related neurological diseases.
Presence of a caregiver(s) responsible for ensuring treatment compliance and potentially with authority to make medical decisions for the patient if the patient is not competent to make those decisions.
A statement from each patient's physician that indicates the patient has the ability to understand and consent on their own AND they have the willingness to sign CareONE's patient consent.

Exclusion criteria

Patient has Seizures, Epilepsy, uncontrolled Depression, uncontrolled Bipolar disorder, psychotic disorders, alcoholism or drug addiction
Presence of metal implants in the head, except for metal dental implants
Patient has hypertension that is unresponsive to anti-hypertensive medications
Patient has implanted medication pumps unless cleared by physician
Patient has significant heart disease, as determined by a physician